Digital Media briefs

Share this article:
Sermo launched Sermo Mobile, an app allowing docs to access medical information in real-time. Sermo Mobile's iConsult feature lets physicians take a photograph of a physical ailment, x-ray or lab result, choose a question from the set list of applicable health queries, and send the message to relevant specialists in the Sermo network of physicians instantaneously. Other highlights include easy access to the Sermo community's discussions about healthcare reform and clinical trials, the ability to author and track posts, and notifications that keep members flagged for new developments in medicine.

DDMAC issued an untitled letter to Cephalon for an HCP website for Trisenox, indicated for the treatment of acute promyelocytic leukemia. The letter said the website “broadens the indication for Trisenox, minimizes and omits risks associated with the use of Trisenox, presents misleading and unsubstantiated claims, and overstates the efficacy of the drug.”

The Alzheimer's Association partnered with AOL's MapQuest for a “site takeover” plugging the Alzheimer's Association's Walk to End Alzheimer's, including a Map Toolbar icon allowing users to search for walks near them.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?